These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37195445)

  • 1. Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.
    Geist BK; Brath H; Zisser L; Yu J; Fueger B; Nics L; Patronas EM; Kautzky-Willer A; Hacker M; Rasul S
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3034-3041. PubMed ID: 37195445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using
    Rasul S; Geist BK; Brath H; Baltzer P; Sundar LKS; Pichler V; Mitterhauser M; Kautzky-Willer A; Hacker M
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32205328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vivo Functional Assessment of Sodium-Glucose Cotransporters (SGLTs) Using [
    Matsusaka Y; Chen X; Arias-Loza P; Werner RA; Nose N; Sasaki T; Rowe SP; Pomper MG; Lapa C; Higuchi T
    Mol Imaging; 2022; 2022():4635171. PubMed ID: 35903251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).
    Brunton S; Rozjabek HM; Pilon D; Lafeuille MH; Kamstra R; Wynant W; Bookhart BK; Lefebvre P
    Curr Med Res Opin; 2019 Sep; 35(9):1607-1614. PubMed ID: 30964362
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship Between HbA1c Level and Effectiveness of SGLT2 Inhibitors in Decompensated Heart Failure Patients with Type 2 Diabetes Mellitus.
    Nakagaito M; Imamura T; Joho S; Ushijima R; Nakamura M; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):843-849. PubMed ID: 34276009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.
    Scafoglio CR; Villegas B; Abdelhady G; Bailey ST; Liu J; Shirali AS; Wallace WD; Magyar CE; Grogan TR; Elashoff D; Walser T; Yanagawa J; Aberle DR; Barrio JR; Dubinett SM; Shackelford DB
    Sci Transl Med; 2018 Nov; 10(467):. PubMed ID: 30429355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
    D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
    Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
    Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
    D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
    JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Yagi S; Aihara KI; Kondo T; Kurahashi K; Yoshida S; Endo I; Fukuda D; Nakaya Y; Suwaki KI; Takeji T; Wada T; Salim HM; Hama S; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Tobiume T; Yamada H; Soeki T; Wakatsuki T; Matsuhisa M; Shimabukuro M; Akaike M; Sata M
    Adv Ther; 2018 Jan; 35(1):124-134. PubMed ID: 29185199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
    Goldenberg RM
    Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
    Hirai T; Kawagoe Y; Kei M; Ogawa R; Itoh T
    Biol Pharm Bull; 2020; 43(5):782-787. PubMed ID: 32378557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional expression of sodium-glucose transporters in cancer.
    Scafoglio C; Hirayama BA; Kepe V; Liu J; Ghezzi C; Satyamurthy N; Moatamed NA; Huang J; Koepsell H; Barrio JR; Wright EM
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4111-9. PubMed ID: 26170283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration.
    George J; Lobkovich A; Nardolillo J; Farhat N; Kolander S; Thomas E
    Am J Health Syst Pharm; 2022 Jul; 79(14):1151-1157. PubMed ID: 35136945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
    Liu Z; Ma X; Ilyas I; Zheng X; Luo S; Little PJ; Kamato D; Sahebkar A; Wu W; Weng J; Xu S
    Theranostics; 2021; 11(9):4502-4515. PubMed ID: 33754074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
    van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
    Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.